Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease
Jaya Prakash N. Ambinathan(University of Toronto), David Z.I. Cherney(University Health Network), Petter Bjornstad(University of Colorado Denver), Vikas S. Sridhar(University Health Network), Yuliya Lytvyn(University Health Network), Julie A. Lovshin(Sunnybrook Health Science Centre), Bruce A. Perkins(Sinai Health System), Hongyan Liu, Leif Erik Lovblom(Mount Sinai Hospital)
Cited by 16
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
|American Journal of Physiology-Renal Physiology|2014|173